 InPharm | Zytiga cost too high, says NICE InPharm Zytiga (abiraterone) is not recommended, in combination with steroids prednisone or prednisolone, as a second-line treatment for metastatic, castration-resistant prostate cancer in patients who have failed on Sanofi's Taxotere. NICE draft "no" for Zytiga Charities condemn 'no' decision on prostate drug NICE turns down 'expensive' prostate cancer drug |
